A blockbuster AstraZeneca drug might now be used as an earlier therapy for mantle cell lymphoma (MCL), making it the primary in its class authorised as a first-line remedy for this uncommon and aggressive sort of blood most cancers.
The FDA expanded approval of the drug, acalabrutinib, to incorporate beforehand untreated MCL in adults who’re additionally ineligible for a hematopoietic stem cell transplant that may be a therapy choice for youthful sufferers. As a first-line remedy, the AstraZeneca drug have to be utilized in mixture with bendamustine and rituximab, a drug routine typically used for older MCL sufferers. The late Thursday regulatory choice additionally grants conventional approval to the drug as a single-agent therapy for adults whose MCL has acquired an earlier line of remedy.
MCL is sort of B cell non-Hodgkin lymphoma, a most cancers of the lymphatic system. Chemotherapy is the usual therapy, however relapse is frequent. Acalabrutinib, marketed underneath the model title Calquence, is a small molecule designed to dam Bruton’s tyrosine kinase (BTK), an enzyme that promotes the proliferation and survival of malignant B cells.
Calquence, a twice-daily capsule, initially gained accelerated FDA approval in 2017 as a therapy for adults whose MCL has acquired at the least one prior remedy. In 2019, the AstraZeneca drug’s label expanded to incorporate persistent lymphocytic leukemia or small lymphocytic leukemia. Calquence is certainly one of AstraZeneca’s high oncology merchandise, accounting for $2.5 billion in income in 2023, up 25% from the prior yr.
The newest FDA approval for Calquence relies on the outcomes of ECHO, a Section 3 examine that enrolled 598 sufferers age 65 and older with untreated MCL. These contributors had been randomly assigned to obtain the examine drug plus the bendamustine/rituximab routine, or a placebo and bendamustine/rituximab.
At a median follow-up of 49.8 months, scientific trial outcomes confirmed longer progression-free survival that was statistically vital. Median progression-free survival was 66.4 months within the examine drug arm versus 49.6 months within the comparator group. The Section 3 knowledge had been introduced final June through the annual assembly of the European Hematology Affiliation in Madrid.
“Managing this aggressive most cancers requires maximizing efficacy whereas sustaining tolerability, particularly for aged sufferers,” Michael Wang, director of the Mantle Cell Lymphoma Program of Excellence at MD Anderson Most cancers Heart and principal investigator within the trial, stated in a ready assertion included in AstraZeneca’s approval announcement. “Outcomes from the pivotal ECHO trial spotlight the promise of the acalabrutinib mixture in defining a brand new customary of care, with right now’s approval underscoring the transformative potential of this routine as a first-line therapy for older sufferers with mantle cell lymphoma.”
Calquence’s new FDA approval makes it the primary BTK inhibitor authorised as a first-line MCL therapy. That provides the drug an edge over others in its class. Eli Lilly’s BTK inhibitor, Jaypirca, landed FDA approval in 2023 as a third-line therapy for MCL. Imbruvica, marketed by Johnson & Johnson and AbbVie, and Brukinsa, from BeiGene (which is altering its title to BeOne Medicines), are each authorised as second-line therapies for MCL.
Picture: Christopher Furlong, Getty Pictures
